	OS (median, days)		
	RPA1	RPA2	RPA3
p	0.0342	0.0002	n.s.
Breast cancer	422	170	70
Lung adenocarcinoma	289	160	39
Small cell lung cancer	248	119	37
Squamous lung cancer; melanoma; GE cancer; others; primary unknown	144	93	56
Kidney; Ovary/Uterus	324	820	78

Multivariate analysis confirms the impact of histology on overall survival along with the other known prognostic factors (RPA classes, dose of HWBRT, combination of surgery and radiotherapy).
Discussion: Histology of the primary is an independent and strong prognostic factor for OS in BM pts treated with HWBRT. More advanced statistical analysis on larger numbers is needed to confirm these results.

References

[1] Recursive partitioning analysis (RPA) of prognostic factors in the three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Gaspar L; Scott C; Rotman M; Asbell S; Phillips T; Wasserman T; Mc Kenna G; Byhardt R Int. J. Radiation Oncol vol 37, 4; 745−751 1997

8729 POSTER

The effectiveness of radiosensitized tumor treatment in brain metastases of different histogenesis

L. Bloznelyte-Plesniene[1], D. Sendiuliene[1]. [1]*Institute of Oncology of Vilnius University, Laboratory of Laser and Photodynamic Treatment, Vilnius, Lithuania*

Background: The prognosis of the vast majority of patients who develop brain metastases (BM) is poor. The best treatment strategy remains unknown for a large group of patients affected by BM. The aim of this work was to investigate the possibilities of sensitized malignant tumor treatment using some derivatives of hematoporphyrin (HpD) as a radiosensitizer in brain metastases of different histogenesis.
Material and Methods: From 2000 to 2009 the total of 64 patients with BM underwent radiosensitized tumor treatment (RST). There were 35 patients with previously untreated BM, 12 patients with recurrent BM after neurosurgery and 20 patients underwent radiotherapy until RST. The histological examination of primary (42 patients) or secondary (12 patients) tumor revealed: melanoma in 22 cases, adenocarcinoma in 30, adenoid cystic carcinoma in 5, sarcoma in 4, and other tumors in 3 cases. HpD was injected i.v.; 24, 48 and 72h after injection of the sensitizer tumors were irradiated with gamma rays 2 Gy at a time from radioactive ^{60}Co (the full dose of the course was 6 Gy). At the start of the treatment Karnofsky performance scale index was <70% in 59 patients.
Results: As the immediate result of RST, the Karnofsky performance scale index increased in 52 patients after the treatment. All malignant brain tumors fully disappeared in 14 patients. Among these 14 patients there were 5 patients with adenocarcinoma, 2 patients with melanoma, 1 patient with sarcoma, 1 patient with neuroblastoma and 5 (all treated) patients with adenoid cystic carcinoma. CT or MRI examinations, provided 3−6 weeks after each RST course, revealed the partial regression of tumor in 32 patients. The median survival of 64 patients (from the moment of brain metastases detection) treated by the addition of RST was 12 months. Comparing it with the 4.5 months median survival of 184 control group patients, it was statistically significant longer. The median survival of 22 patients with metastatic melanoma was 10 months, and with metastatic adenocarcinoma (30 patients) – 12 months. The median survival of 64 patients from the first course of RST was 7 months.
Conclusions: RST - effective method of treatment in metastatic brain tumors, especially when it is applied for adenoid cystic carcinoma. The tumors of different histogenesis require some RST modifications.

8730 POSTER

Malignant melanoma brain metastases – a single institution experience

M. Conçalves[1], A. Passos[1], A. Moreira[1], J. Oliveira[1]. [1]*Portuguese Institute of Oncology, Medical Oncology, Lisbon, Portugal*

Background: Brain metastases (BM) develop in nearly half of the patients with advanced melanoma representing the cause of death in up to 54%. The limited array of treatment options and the conflicting data on the role of radiation in this group of patients represents a challenging issue in cancer treatment. The purpose of this study was to analyse cerebral involvement of melanoma according to treatment options.
Materials and Methods: The authors reviewed the records and confirmed survival status of all patients with BM from cutaneous melanoma between 1998 and 2004. Cases were grouped according to the treatment received: 1) Supportive Care (SC), 2) Whole Brain Radiotherapy (WBRT), and 3) Surgery+ Whole Brain Radiotherapy (S+WBRT).
Results: Forty-nine patients were identified, all dead as a result of melanoma progression, with median survival from onset of BM metastases of 12 weeks. Stratifying, 51% patients were in the SC group (n = 25), 34% in the WBRT (n = 17) and 14% S+WBRT(n = 7). The median age of diagnosis was similar in the first two groups (60.7 and 62.6 years) but lower in the third group (48.8 years). Karnovsky performance status was only registered in 15 patients (30%). The majority (n = 44) had systemic disease but in 18 SC cases (72%) more than two sites of metastases were found compared to 35% in the WBRT and 40% in S+WBRT. Multiple metastases (>4 lesions) in 16 patients in the SC (64%) and 11 in WBRT (64%). All the patients in S+WBRT had between 1 and 3 lesions. Median survival was 7 weeks in the SC, 16.7 weeks in WBRT and 24,5 weeks in the S+WBRT group. Neurological improvement was seen in 14 SC cases (56%), 15 WBRT (88%) and in all of S+WBRT cases. Thirty nine patients (80%) were on steroids.
Conclusions: Our median survival depended on the treatment modality which in turn seems to be influenced by patient selection, an important bias in this data. Its is extremely difficult to access the palliative benefit of different treatments since the majority of the patients were on steroid therapy.

8731 POSTER

Fractionated Stereotactic Radiotherapy (FSRT) in the management of functioning and non-functioning pituitary adenomas

M. Cabeza[1], M.A. Pérez[1], A. Bartolome[1], E. Cabello[2], A. Fernandez[1], R. Díaz[2], V. Rodríguez[1], A. Ruiz[1], J. Pérez-Regadera[1], E. Lanzos[1]. [1]*Hospital 12 Octubre, Radiation Oncology, Madrid, Spain;* [2]*Hospital 12 Octubre, Radiation Physics, Madrid, Spain*

Background: FSRT has been developed as more accurate technique of irradiation with more precise tumor localization and delivery and consequently a reduction in the volume of normal tissue. FSRT is not limited by dimensions or distance from CTV to optic system. The objective was to assess the outcome in a cohort of patients with residual or recurrent pituitary adenoma treated with FSRT.
Materials and Methods: Fifty patients (median age 45 years) with a residual or recurrent nonfunctioning (21) or functioning (19) pituitary adenomas were treated between 1997 and 2007. Fifteen patients had an ACTH-secreting, nine GH-secreting and five PRL-secreting pituitary adenoma. Eleven patients had partial or complete hypopituitarism before FSRT. Visual field defect had 10 patients. The treatment was delivered stereotactically, using a Gill-Thomas-Cosman recolocable guide and four noncoplanar arcs with circular focalized collimators with 6. MV LINAC to a dose of 46 Gy in 23 fractions. PTV was defined as GTV+5 mm margin.
Results: At a median follow-up of 68 months (range 14−143), the 5 and 8 years actuarial progression free survival is 98% and 98%, and overall survival is 98%. One patient relapsed 45 months after FSRT. In secreting adenomas hormone levels declined progressively, with hormonal control actuarial at 5 years in ACTH-secreting adenomas in 61%, GH-secreting adenomas in 46% (GH/IGF-1 levels). The hormone levels become normal in one of five, PRL-secreting pituitary adenoma. Hypopituitarism was the most common long-term effect; Pituitary dysfunction was observed, in different grade in patients with normal pituitary function or with partial hypopituitarism, the rates at 5 and 8 years estimated with Kaplan–Meier survival was 27% and 53%. Non visual complications occurred following FSRT.
Conclusions: FSRT as a high-precision technique of localized irradiation achieves tumor and hormone control of pituitary adenomas comparable with previously published date on the efficacy of conventional radiotherapy, the theoretical benefit over conventional radiotherapy in terms of the reduction in long-term morbidity has not yet been demonstrated and requires longer follow-up

8732 POSTER

Ten years' experience with stereotactic radiotherapy for pituitary adenoma

N. Patil[1], J. Brierley[1], M. van Prooijen[2], M. Heydarian[2], S. Mckinnon[3], S. Ladak[3], S. Fung[4], R. Tsang[1]. [1]*Princess Margaret Hospital University of Toronto, Radiation Oncology, Toronto ON, Canada;* [2]*Princess Margaret Hospital University of Toronto, Radiation Physics, Toronto ON, Canada;* [3]*Princess Margaret Hospital University of Toronto, Radiation Therapy, Toronto ON, Canada;* [4]*Princess Margaret Hospital University of Toronto, Biostatistics, Toronto ON, Canada*

Purpose: To evaluate local control and toxicity for pituitary adenomas treated with stereotactic radiotherapy (SRT).